A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

This study is looking for adults who have advanced liver cancer (hepatocellular carcinoma) that either can't be removed with surgery or has spread to other parts of the body. Your doctor will need to confirm your diagnosis, usually through special tests.

To be suitable, your liver cancer should be at a specific stage (BCLC Stage B or C), and your liver function also needs to be within a certain range (Child-Pugh A or B7). You should also generally be well enough to take part in a study, meaning you can mostly look after yourself and do light activities (according to a score called ECOG Performance Status of 0 or 1).

You wouldn't be able to join if you've already had other treatments for your liver cancer, have brain tumours that are causing symptoms or growing, or have had another type of cancer in the past (unless it was treated a long time ago and is not expected to return).

If you decide to take part in this study, you'll be given one of the drug combinations being tested. All the study drugs will be given directly into your vein (intravenously) through a drip. Depending on which treatment group you're in, you’ll receive these infusions either every three weeks or every four weeks.

You will need to attend regular visits at a hospital or clinic. These appointments will involve various medical checks, including blood tests, answering questionnaires about your health, and having scans to see how the treatment is affecting your cancer. You’ll continue with the treatment until your cancer gets worse or if you need to stop for other reasons. The study estimates that you might be involved for about 56 months in total.